Stryker Corp SYK posted Q4 adjusted EPS of $2.71, down 3.6% Y/Y, missing the consensus of $2.72.
- "We delivered a strong year of financial results, despite the ongoing challenges of the pandemic," said Kevin Lobo, Chair & CEO. "Organic sales growth of over 7% versus 2019, coupled with double-digit adjusted EPS growth and excellent cash flow performance were all noteworthy achievements, as was the excellent integration of Wright Medical."
- Consolidated net sales of $4.7 billion increased 10.3% Y/Y (11.1% in constant currency), beating the estimate of $4.65 billion.
- Organically, sales were up 6.2%, including 7.9% from the higher unit volume, partially offset by 1.7% from lower prices, versus the 2019 quarter.
- MedSurg and Neurotechnology segment clocked net sales of $2.64 billion, +8.7% Y/Y (+9.2% organic).
- Orthopedics & Spine sales reached $2.06 billion, up 12.5% Y/Y (+8.7% organically).
- The adjusted gross margin increased marginally to 65.8% from 65.1% posted a year ago. The operating margin declined from 29.2% to 27.3%.
- Guidance: Stryker notes short-term outlook remains volatile based on the assessment of the impact of the pandemic on its operations and the external environment.
- Stryker expects FY22 organic net sales growth of 6% - 8% and adjusted EPS of $9.60 - $10.00, compared to the consensus of $10.14.
- The company expects continued unfavorable price reductions of approximately 1% in 2022.
- If foreign exchange rates hold near their current levels, Stryker anticipates sales and EPS will be modestly unfavorably impacted compared to 2021.
- Price Action: SYK shares closed lower by 1.18% at $245.33 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in